Adalimumab for maintenance of remission in Crohn's disease

BACKGROUND: Conventional medications for Crohn's disease (CD) include anti‐inflammatory drugs, immunosuppressants and corticosteroids. If an individual does not respond, or loses response to first‐line treatments, then biologic therapies such as tumour necrosis factor‐alpha (TNF‐α) antagonists...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cochrane Database Syst Rev
Hoofdauteurs: Townsend, Cassandra M, Nguyen, Tran M, Cepek, Jeremy, Abbass, Mohamad, Parker, Claire E, MacDonald, John K, Khanna, Reena, Jairath, Vipul, Feagan, Brian G
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley & Sons, Ltd 2020
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7386457/
https://ncbi.nlm.nih.gov/pubmed/32413933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012877.pub2
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items